NYSE:CBM - Cambrex Stock Price, Forecast & News

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analyst estimates of $132.78 million. Cambrex had a return on equity of 5.38% and a net margin of 5.96%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 earnings per share. View Cambrex's Earnings History.

4 brokerages have issued 12-month price targets for Cambrex's stock. Their forecasts range from $44.00 to $60.00. On average, they expect Cambrex's stock price to reach $54.75 in the next twelve months. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for Cambrex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Media headlines about CBM stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cambrex earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cambrex.

Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Under Armour (UAA), Broadcom (AVGO) and Juno Therapeutics (JUNO).

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.99.

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]